Hims & Hers Health (HIMS) stock slipped 1% pre‑market after CFO Oluyemi Okupe filed to sell nearly $5 million in shares. The insider sale follows a 6% rally driven by the launch of a new lineup of Novo Nordisk GLP‑1 therapies. This expansion comes after a legal settlement allowing Hims to offer FDA‑approved weight‑loss treatments.